A Study to Assess the Efficacy and Safety of Oral CL-H1T in the Treatment of Acute Migraine Pain
A Study to Assess the Efficacy and Safety of Oral CL-H1T in the Treatment of Acute Migraine Pain, With or Without Aura, and the Prevention of Migraine Associated Nausea and Vomiting.
Sponsor: Charleston Laboratories, Inc
Listed as NCT03877718, this PHASE2 trial focuses on Aura and Migraine and remains completed. Sponsored by Charleston Laboratories, Inc, it has been updated 5 times since 2019, reflecting limited change activity. This study adds to the evidence base for this therapeutic area through structured, versioned documentation.
Status Flow
Change History
5 versions recorded-
Sep 2024 — Present [monthly]
Completed PHASE2
-
Jul 2024 — Sep 2024 [monthly]
Completed PHASE2
-
Jan 2021 — Jul 2024 [monthly]
Completed PHASE2
-
Dec 2019 — Jan 2021 [monthly]
Completed PHASE2
Status: Recruiting → Completed
-
Apr 2019 — Dec 2019 [monthly]
Recruiting PHASE2
First recorded
Feb 2019
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Charleston Laboratories, Inc
For direct contact, visit the study record on ClinicalTrials.gov .